Grace Halsey

Risk of dementia was more than 60% lower among adults aged 60 to 69 years with hearing loss who used hearing aids in the first study to highlight early intervention.

William Schaffner, MD, ID specialist and vaccine expert, advises following state guidance on back-to-school shots and thinking through new guidance on COVID shots for kids.

The statistically significant improvements seen in key HS symptoms during GLP-1 treatment for obesity suggest overlap in both mechanistic and immunologic effects.

The GLP-1/GIP receptor agonist also showed promise in an exploratory maintenance arm, producing rapid weight loss at an induction dose that was sustained after down-titration.

In the RE104 group receiving the 30-mg dose, clinically meaningful reductions in the primary endpoint were seen on day 1 posttreatment and sustained through day 28 follow-up.

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.

Updates to the 2017 guideline focus on new monitoring strategies, earlier intervention to reduce cognitive decline, improved perinatal care, and refined risk assessment.

Please remind your adult patients that these recommended vaccines (eg, pneumococcal, flu, HPV) are essential to protect them, and their communities, from serious outcomes.

GLP-1 use among adults with diabetes peaked among those aged 50 to 64 years, was highest among Hispanic adults, and was more likely among those taking other antihyperglycemic agents.

William Schaffner, MD, a veteran infectious disease expert and public health thought leader is concerned that rapidly shifting federal policy could impact future options.

Fewer than 1 in 5 eligible older adults in the US received the RSV vaccine during the first 2 seasons it was available, and uptake was lower based on SDOH.

RDX-002, an investigational, first-in-class therapeutic, significantly reduced weight regain after cessation of antiobesity treatment with semaglutide and tirzepatide.

The 9 influenza vaccines available for the upcoming respiratory virus season come from 4 manufacturers in single-dose syringes and vials and multidose vials may still be available.

Jonathan Bonnet, MD, MPH, board certified in lifestyle and obesity medicine, explains how the 6 pillars of the former are essential to success in the latter.

Danish adults aged 65 and older at high-risk for serious infection with SARS-CoV-2 showed no increased risk of 29 serious adverse events following vaccination.

Schaffner describes the mood among his colleagues in infectious disease right now as anxious, perplexed, distressed, and angry. They expect the disruptions and their feelings to continue.

The FDA Fast Track designation for NRX-100 (IV, preservative-free ketamine) expands by 10-fold the potential treatment population that seriously considers suicide.

Insulin delivered via nasal spray in this first-in-human PET imaging study was observed in 11 key brain areas relevant to cognitive decline, validating a new research avenue.

The oral peptide that selectively targets IL-23 offers a novel approach to quelling the inflammatory process that underlies plaque psoriasis.

The obesity and lifestyle medicine specialist says while research on the question continues, a focus on optimizing nutritional health during treatment is essential.

Health information permeates social media platforms exposing Americans to advice, even when they don't want it. The good news? Not many trust it!

The 2 new plasma assays to enhance Alzheimer’s disease research will support disease staging, predicting disease progression, and monitoring treatment outcome.

Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.

The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.

Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.

Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.

An NHANES-based cross sectional study found that 1 in 5 of the treatment-eligible youth lacked adequate insurance and one-third had no routine place for health care.

If primary care clinicians are to meet the cognitive screening demands that are growing with an aging population, they need the sharpest tools in the box, this expert says.

A cognitive health assessment will soon be as routine as taking blood pressure or pulse oximetry, says neurocognitive researcher David J. Libon, PhD. He talks more about that future.